512 related articles for article (PubMed ID: 7555508)
1. Reduction of glycosylated hemoglobin and postprandial hyperglycemia by acarbose in patients with NIDDM. A placebo-controlled dose-comparison study.
Coniff RF; Shapiro JA; Robbins D; Kleinfield R; Seaton TB; Beisswenger P; McGill JB
Diabetes Care; 1995 Jun; 18(6):817-24. PubMed ID: 7555508
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of acarbose in insulin-treated patients with type 2 diabetes.
Kelley DE; Bidot P; Freedman Z; Haag B; Podlecki D; Rendell M; Schimel D; Weiss S; Taylor T; Krol A; Magner J
Diabetes Care; 1998 Dec; 21(12):2056-61. PubMed ID: 9839094
[TBL] [Abstract][Full Text] [Related]
3. Acarbose in NIDDM patients with poor control on conventional oral agents. A 24-week placebo-controlled study.
Lam KS; Tiu SC; Tsang MW; Ip TP; Tam SC
Diabetes Care; 1998 Jul; 21(7):1154-8. PubMed ID: 9653611
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of acarbose in metformin-treated patients with type 2 diabetes.
Rosenstock J; Brown A; Fischer J; Jain A; Littlejohn T; Nadeau D; Sussman A; Taylor T; Krol A; Magner J
Diabetes Care; 1998 Dec; 21(12):2050-5. PubMed ID: 9839093
[TBL] [Abstract][Full Text] [Related]
5. Multicenter, placebo-controlled trial comparing acarbose (BAY g 5421) with placebo, tolbutamide, and tolbutamide-plus-acarbose in non-insulin-dependent diabetes mellitus.
Coniff RF; Shapiro JA; Seaton TB; Bray GA
Am J Med; 1995 May; 98(5):443-51. PubMed ID: 7733122
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of 24-week monotherapy with acarbose, glibenclamide, or placebo in NIDDM patients. The Essen Study.
Hoffmann J; Spengler M
Diabetes Care; 1994 Jun; 17(6):561-6. PubMed ID: 8082525
[TBL] [Abstract][Full Text] [Related]
7. Acarbose in ambulatory treatment of non-insulin-dependent diabetes mellitus associated to imminent sulfonylurea failure: a randomised-multicentric trial in primary health-care. Diabetes and Acarbose Research Group.
Costa B; Piñol C
Diabetes Res Clin Pract; 1997 Oct; 38(1):33-40. PubMed ID: 9347244
[TBL] [Abstract][Full Text] [Related]
8. A double-blind placebo-controlled trial evaluating the safety and efficacy of acarbose for the treatment of patients with insulin-requiring type II diabetes.
Coniff RF; Shapiro JA; Seaton TB; Hoogwerf BJ; Hunt JA
Diabetes Care; 1995 Jul; 18(7):928-32. PubMed ID: 7555551
[TBL] [Abstract][Full Text] [Related]
9. An Asian multicenter clinical trial to assess the efficacy and tolerability of acarbose compared with placebo in type 2 diabetic patients previously treated with diet. Asian Acarbose Study Group.
Chan JC; Chan KW; Ho LL; Fuh MM; Horn LC; Sheaves R; Panelo AA; Kim DK; Embong M
Diabetes Care; 1998 Jul; 21(7):1058-61. PubMed ID: 9653595
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic potentials of acarbose as first-line drug in NIDDM insufficiently treated with diet alone.
Hanefeld M; Fischer S; Schulze J; Spengler M; Wargenau M; Schollberg K; Fücker K
Diabetes Care; 1991 Aug; 14(8):732-7. PubMed ID: 1954810
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of 24-week monotherapy with acarbose, metformin, or placebo in dietary-treated NIDDM patients: the Essen-II Study.
Hoffmann J; Spengler M
Am J Med; 1997 Dec; 103(6):483-90. PubMed ID: 9428831
[TBL] [Abstract][Full Text] [Related]
12. Long-term effect of acarbose on glycaemic control in non-insulin-dependent diabetes mellitus: a placebo-controlled double-blind study.
Hotta N; Kakuta H; Sano T; Matsumae H; Yamada H; Kitazawa S; Sakamoto N
Diabet Med; 1993 Mar; 10(2):134-8. PubMed ID: 8458189
[TBL] [Abstract][Full Text] [Related]
13. Efficacy, safety, and dose-response characteristics of glipizide gastrointestinal therapeutic system on glycemic control and insulin secretion in NIDDM. Results of two multicenter, randomized, placebo-controlled clinical trials. The Glipizide Gastrointestinal Therapeutic System Study Group.
Simonson DC; Kourides IA; Feinglos M; Shamoon H; Fischette CT
Diabetes Care; 1997 Apr; 20(4):597-606. PubMed ID: 9096986
[TBL] [Abstract][Full Text] [Related]
14. European study on dose-response relationship of acarbose as a first-line drug in non-insulin-dependent diabetes mellitus: efficacy and safety of low and high doses.
Fischer S; Hanefeld M; Spengler M; Boehme K; Temelkova-Kurktschiev T
Acta Diabetol; 1998 Apr; 35(1):34-40. PubMed ID: 9625287
[TBL] [Abstract][Full Text] [Related]
15. Long-term efficacy and safety of acarbose in the treatment of obese subjects with non-insulin-dependent diabetes mellitus.
Coniff RF; Shapiro JA; Seaton TB
Arch Intern Med; 1994 Nov; 154(21):2442-8. PubMed ID: 7979840
[TBL] [Abstract][Full Text] [Related]
16. One-year acarbose treatment raises fasting serum acetate in diabetic patients.
Wolever TM; Radmard R; Chiasson JL; Hunt JA; Josse RG; Palmason C; Rodger NW; Ross SA; Ryan EA; Tan MH
Diabet Med; 1995 Feb; 12(2):164-72. PubMed ID: 7743764
[TBL] [Abstract][Full Text] [Related]
17. Acarbose in the treatment of type I diabetes.
Hollander P; Pi-Sunyer X; Coniff RF
Diabetes Care; 1997 Mar; 20(3):248-53. PubMed ID: 9051366
[TBL] [Abstract][Full Text] [Related]
18. Beneficial effects on serum lipids in noninsulin dependent diabetics by acarbose treatment.
Leonhardt W; Hanefeld M; Fischer S; Schulze J; Spengler M
Arzneimittelforschung; 1991 Jul; 41(7):735-8. PubMed ID: 1772463
[TBL] [Abstract][Full Text] [Related]
19. A comparison of acarbose versus metformin as an adjuvant therapy in sulfonylurea-treated NIDDM patients.
Bayraktar M; Van Thiel DH; Adalar N
Diabetes Care; 1996 Mar; 19(3):252-4. PubMed ID: 8742572
[TBL] [Abstract][Full Text] [Related]
20. The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus. A multicenter controlled clinical trial.
Chiasson JL; Josse RG; Hunt JA; Palmason C; Rodger NW; Ross SA; Ryan EA; Tan MH; Wolever TM
Ann Intern Med; 1994 Dec; 121(12):928-35. PubMed ID: 7734015
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
